About COP9 signalosome complex subunit 1
COP9 signalosome complex subunit 1 (GPS1) is a protein
from Homo sapiens identified by UniProt accession
Q13098, 491 residues long.
MolForge cross-references it against 0 known binders and
39 disease associations.
Target properties
| Protein name | COP9 signalosome complex subunit 1 |
| UniProt accession | Q13098 |
| Gene | GPS1 |
| Organism | Homo sapiens |
| Length | 491 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (39)
Diseases linked to this target (Open Targets).
- glioblastoma multiforme · score 0.23
- lung adenocarcinoma · score 0.18
- breast adenocarcinoma · score 0.18
- heel bone mineral density · score 0.14
- breast cancer · score 0.07
- esophageal squamous cell carcinoma · score 0.05
- FEV/FVC ratio · score 0.03
- esophageal adenocarcinoma · score 0.02
- cancer · score 0.02
- head and neck squamous cell carcinoma · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q13098-F1 | alphafold | PREDICTED | 84.63 | — |
Amino-acid sequence (491 residues)
MPLPVQVFNL QGAVEPMQID VDPQEDPQNA PDVNYVVENP SLDLEQYAAS YSGLMRIERL QFIADHCPTL RVEALKMALS FVQRTFNVDM YEEIHRKLSE ATRSSLRELQ NAPDAIPESG VEPPALDTAW VEATRKKALL KLEKLDTDLK NYKGNSIKES IRRGHDDLGD HYLDCGDLSN ALKCYSRARD YCTSAKHVIN MCLNVIKVSV YLQNWSHVLS YVSKAESTPE IAEQRGERDS QTQAILTKLK CAAGLAELAA RKYKQAAKCL LLASFDHCDF PELLSPSNVA IYGGLCALAT FDRQELQRNV ISSSSFKLFL ELEPQVRDII FKFYESKYAS CLKMLDEMKD NLLLDMYLAP HVRTLYTQIR NRALIQYFSP YVSADMHRMA AAFNTTVAAL EDELTQLILE GLISARVDSH SKILYARDVD QRSTTFEKSL LMGKEFQRRA KAMMLRAAVL RNQIHVKSPP REGSQGELTP ANSQSRMSTN M
Explore COP9 signalosome complex subunit 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets